VERU Insider Trading

Insider Ownership Percentage: 14.90%
Insider Buying (Last 12 Months): $69,102.84
Insider Selling (Last 12 Months): $250,075.35

Veru Insider Trading History Chart

This chart shows the insider buying and selling history at Veru by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$2M-$1M$0$1M$2MTotal Insider BuyingTotal Insider Selling

Veru Share Price & Price History

Current Price: $0.52
Price Change: Price Decrease of -0.0141 (-2.62%)
As of 04/28/2025 05:00 PM ET

This chart shows the closing price history over time for VERU up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JunJulAugSepOctNovDecJanFebMarApr$0.52Closing price on 04/28/25:

Veru Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Veru (NASDAQ:VERU)

47.16% of Veru stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at VERU by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$299kbought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$5M$0$5MTotal InflowsTotal Outflows
Veru logo
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Read More on Veru

Today's Range

Now: $0.52
Low: $0.51
High: $0.55

50 Day Range

MA: $0.53
Low: $0.45
High: $0.64

52 Week Range

Now: $0.52
Low: $0.45
High: $1.75

Volume

543,581 shs

Average Volume

1,806,352 shs

Market Capitalization

$76.69 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Veru?

Veru's top insider shareholders include:
  1. Mitchell Shuster Steiner (CEO)
  2. Harry Fisch (Insider)
  3. Michael L Rankowitz (Director)
  4. K Gary Barnette (Insider)
Learn More about top insider investors at Veru.

Who are the major institutional investors of Veru?

Veru's top institutional investors include:
  1. Cambridge Investment Research Advisors Inc. — 0.97%
  2. Oppenheimer & Co. Inc. — 0.91%
  3. 180 Wealth Advisors LLC — 0.30%
  4. Weaver Consulting Group — 0.06%
Learn More about top institutional investors of Veru stock.

Which institutional investors are buying Veru stock?

During the previous quarter, VERU stock was acquired by institutional investors including:
  1. Cambridge Investment Research Advisors Inc.
  2. Oppenheimer & Co. Inc.
  3. 180 Wealth Advisors LLC
  4. Weaver Consulting Group
In the previous year, these company insiders have bought Veru stock:
  1. Mitchell Shuster Steiner (CEO)
  2. Harry Fisch (Insider)
  3. Michael L Rankowitz (Director)
Learn More investors buying Veru stock.